SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Surya Pharmaceutical gains on receiving COS for Cefalexin Monohydrate

20 Apr 2012 Evaluate

Surya Pharmaceutical is currently trading at Rs. 8.64, up by 0.51 points or 6.27% from its previous closing of Rs. 8.13 on the BSE.

The scrip opened at Rs. 8.20 and has touched a high and low of Rs. 8.84 and Rs. 8.15 respectively. So far 2,02,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 25.25 on 21-Apr-2011 and a 52 week low of Rs. 7.56 on 19-Apr-2012.

Last one week high and low of the scrip stood at Rs. 10.85 and Rs. 7.56 respectively. The current market cap of the company is Rs. 175.00 crore.

The promoters holding in the company stood at 38.11% while Non-Institutions hold 42.87% respectively.

Surya Pharmaceutical has received certificate of suitability (COS) for Cefalexin Monohydrate from European Directorate for the Quality of Medicines (EDQM), in addition to already approved Cefixime.

Further, the company's Banur plant has also been approved by Teva for the supply of Intermediates. These developments and the expected approvals from USFDA/TGA/MCA/MCC will help the company service its debt obligation post restructuring.

Besides, the State Bank of India as the lead bank of the consortium of bankers of Surya Pharmaceutical has referred the company for restructuring of its debt to the corporate debt restructuring cell, Mumbai and the company has been admitted by CDR Cell with the support of majority of lenders.

Surya Pharmaceutical is engaged in manufacturing of active pharmaceutical ingredients (API's), finished drug formulations (FDF's), fine intermediates, herbal products, and mint/menthol derivatives. The company has client based in over 90 countries across the globe. 

Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×